Clinical trials: Social Anxiety Disorder
Social Phobia
A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills
This study will be conducted in healthy female volunteers to investigate the effect of GW876008 on the pharmacokinetics of oral contraceptive pills.
- Trial name
- NCT00508911
- Testing
- GW876008, COC
- Where
- United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Mood, Depression Disorders
Technology Exposure and Child Health: Wellness Impact and Social Effects: An Observational Product Registry Study
The goal of this study is to understand how children's mobile device usage (smartphones or tablets), including social media use and online games, are related to their mental wellness and mental health, as well as some aspects of…
- Conditions
- Mood, Depression Disorders, Anxiety Disorders, Sleep
- Trial name
- TECHWISE (NCT06664944)
- Where
- United States
- Volunteers
- 912 people, healthy volunteers welcome
- Sponsor
- Aura
Social Anxiety Disorder
Escitalopram in Patients With Social Anxiety Disorder
The purpose of this study is to evaluate the effect of escitalopram after 12 weeks of treatment in patients with Social Anxiety Disorder (SAD), to evaluate proportion of patients who respond to escitalopram during the treatment…
- Trial name
- NCT00902226
- Testing
- Escitalopram
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- H. Lundbeck A/S
Social Phobia
Long-term Study Of Paroxetine in Women and Men
This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD)
- Trial name
- SAD (NCT00264654)
- Testing
- BRL29060A, paroxetine hydrochloride hydrate
- Where
- 3 sites in Japan
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Alzheimer Disease, Agitation,Psychomotor
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from…
- Conditions
- Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS
- Trial name
- CALMA (NCT05543681)
- Testing
- IGC-AD1-Active
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 164 people
- Sponsor
- IGC Pharma, LLC
Emotional Dysregulation, Therapeutic Alliance
Effectiveness of the SoundHeal Multi-Sensory Integrative Therapy Among Justice-Involved Youth
Emotional dysregulation in justice-involved youth (JIY) is a condition that significantly impacts young people, their families, and juvenile justice and public health systems.
- Conditions
- Emotional Dysregulation, Therapeutic Alliance, Depression Disorder, Anxiety Disorders
- Trial name
- HEAL-SLOJSC (NCT07364799)
- Testing
- Multi-sensory emotional regulation intervention (Heal)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- SoundHeal
Social Anxiety Disorder
A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients…
- Trial name
- PREVAIL (NCT05193409)
- Testing
- 225 mg BNC210, 675 mg BNC210
- Where
- 15 sites in United States
- Volunteers
- 151 people
- Sponsor
- Bionomics Limited
Social Phobia
A Combination Therapy In Patients With Social Anxiety Disorder
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of Vestipitant and Paroxetine in patients with Social Anxiety Disorder (SAD)
- Trial name
- NCT00403962
- Testing
- vestipitant/paroxetine
- Where
- 17 sites in Denmark, Germany and 2 more
- Volunteers
- 204 people
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2
This Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve symptoms of anxiety in adult subjects with social anxiety disorder (SAD) during…
- Trial name
- Palisade-2 (NCT05011396)
- Testing
- PH94B Nasal Spray
- Where
- 15 sites in United States
- Volunteers
- 228 people
- Sponsor
- VistaGen Therapeutics, Inc.
Generalized Anxiety Disorder (GAD), Anxiety, Separation
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
- Trial name
- NCT01470469
- Testing
- SPD503 (extended-release Guanfacine hydrochloride)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Shire
Depression, Anxiety
C-STRESS: A Mental Health App for College Students With Depression
The goal of this pilot study is to examine the feasibility of the prototype C-STRESS app with 3 college students from UCI with clinically significant depression (scored ≥ 10 on the Patient Health Questionnaire-9).
- Conditions
- Depression, Anxiety, Stress, Psychological, Mobile Phone Use
- Trial name
- C-STRESS (NCT05776901)
- Testing
- C-STRESS
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Benten Technologies, Inc.
Social Anxiety, Social Anxiety Disorder
The Safety, Acceptability and Efficacy of Alena
The present study is a randomised controlled trial that seeks to investigate the safety, acceptability and efficacy and safety of the Alena CBT programme as a treatment for social anxiety disorder.
- Conditions
- Social Anxiety, Social Anxiety Disorder, Social Anxiety Disorder (Social Phobia)
- Trial name
- NCT05858294
- Testing
- Cognitive Behavioral Therapy programme
- Where
- United Kingdom
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Aya Technologies Limited
Social Anxiety Disorder (SAD)
A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder
This is a double-blind study to evaluate the efficacy and safety of ENX-102 in participants with social anxiety disorder (SAD).
- Trial name
- NCT07193563
- Testing
- ENX-102
- Where
- 20 sites in United States
- Volunteers
- 47 people
- Sponsor
- Engrail Therapeutics INC
Anxiety Disorders
Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)
Preclinical and clinical findings indicate that LEV has some anxiolytic potential. There is reason to believe that compounds with anxiolytic activity may have broad clinical utility across the anxiety spectrum.
- Trial name
- NCT00612859
- Testing
- levetiracetam
- Volunteers
- 217 people
- Sponsor
- UCB Pharma
Vitiligo, Depressive Episode
Mental Health Associations With Vitiligo
This cohort study is a large population-based study in the UK to determine the risks of comorbid mental health conditions (including depression, anxiety and other potential psychological complications of vitiligo) in adults with…
- Conditions
- Vitiligo, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04953338
- Testing
- Exposure of mental health condtion of interest
- Where
- United Kingdom
- Volunteers
- 36,104 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Social Anxiety Disorder
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of…
- Trial name
- AFFIRM-1 (NCT06510504)
- Testing
- 225 mg BNC210
- Where
- 21 sites in United States
- Volunteers
- 370 people
- Sponsor
- Bionomics Limited
Depressive Disorder and Anxiety Disorders
PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients
This six-arm study is being conducted to measure the effect of a combination of paroxetine and vestipitant on the arousal induced by public speaking in Seasonal Effective Disorder (SAD) patients, using functional brain imaging…
- Trial name
- NCT00343707
- Testing
- vestipitant, paroxetine
- Where
- Sweden
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder (SAD)
A Study of NTX-1472 in Social Anxiety Disorder
The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD).
- Trial name
- SOAR (NCT07323784)
- Testing
- NTX-1472
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Newleos Therapeutics, Inc.
Social Phobia
A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder
To compare by neuroimaging techniques and public speaking, the way social anxiety patients respond after the administration of GW876008, GSK561679, alprazolam and placebo
- Trial name
- NCT00555139
- Testing
- GSK561679 tablet, GW876008 tablet, alprazolam
- Where
- 8 sites in Spain
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Social Phobia
Treatment Of Patients With Social Anxiety Disorder
GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.
- Trial name
- NCT00397722
- Testing
- GW876008, paroxetine
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 299 people
- Sponsor
- GlaxoSmithKline